The U.S. Supreme Court is showing some preliminary interest in reviewing biologic drug patents and the proper way to claim them, an issue potentially worth many billions of dollars.

The court on Monday asked Solicitor General Elizabeth Prelogar’s office to weigh in on Amgen v. Sanofi. The question presented is whether Section 112 of the Patent Act requires that patents enable persons of skill in the art to identify and make all of the embodiments of an invention without undue experimentation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]